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ABSTRACT
Aim: Intravenous sedatives used in the paediatric intensive care unit (PICU) need to be
tapered after prolonged use to prevent iatrogenic withdrawal syndrome (IWS). We
evaluated the occurrence of IWS and the levels of sedation before and after conversion
from intravenous midazolam to oral lorazepam.
Methods: This was a retrospective, observational, single cohort study of children under the
age of 18 admitted to the PICU of the Erasmus MC-Sophia Children’s Hospital, Rotterdam,
The Netherlands, between January 2013 and December 2014. The outcome parameters
were the Sophia Observation withdrawal Symptoms (SOS) scale scores and COMFORT
Behaviour scale scores before and after conversion.
Results: Of the 79 patients who were weaned, 32 and 39 had before and after SOS scores
and 77 had COMFORT-B scores. IWS was reported in 15 of 79 patients (19.0%) during
the 48 hours before the start of lorazepam and 17 of 79 patients (21.5%) during the
48 hours after treatment started. Oversedation was seen in 16 of 79 patients (20.3%)
during the 24 hours before substitution and in 30 of 79 patients (38.0%) during the
24 hours after substitution.
Conclusion: The weaning protocol was not able to prevent IWS in all patients, but
converting from intravenous midazolam to oral lorazepam did not increase the incidence.
INTRODUCTION
Most children admitted to a paediatric intensive care unit
(PICU) receive intravenous sedatives and analgesics to
relieve anxiety, distress and pain and to tolerate mechanical
ventilation and other PICU-related procedures. The most
commonly used sedatives and analgesics in paediatrics are
midazolam and opioids (1). Unfortunately, these drugs can
cause iatrogenic withdrawal syndrome (IWS) after pro-
longed use (2).
To prevent IWS, a protocolled approach to taper the
drugs and to regularly monitor withdrawal symptoms and
sedation levels is recommended. Intravenously adminis-
tered medication can be switched to oral dosage forms, to
facilitate gradual weaning without the need for cardiores-
piratory monitoring required for intravenous sedation and
to omit the need for intravenous access. Treatment can then
be continued outside the PICU, and removing intravenous
access lowers the risk of infection. Oral lorazepam has a
long half-life in children, with a median of 17 hours (range
8–53 hours), which prevents large fluctuations in plasma
concentrations, and also has a lack of active metabolites.
That is why it is often used off-label as a substitute for
intravenous midazolam (2–4).
In our local weaning protocol, the calculation of the
initial dose of oral lorazepam was based on a conversion
factor proposed by Tobias et al. (5), which assumed that
lorazepam was twice as potent as midazolam and had a six-
time longer half-life, based on adult data. This lorazepam
starting dose is calculated irrespective of the potential
impact of maturation of lorazepam and midazolam
Abbreviations
COMFORT-B, COMFORT-behaviour scale; IWS, Iatrogenic
withdrawal syndrome; NISS, Nurses Interpretation of Sedation
Score; PICU, Paediatric intensive care unit; SOS, Sophia Obser-
vation withdrawal Symptoms scale.
Key notes
 Intravenous sedatives used in the paediatric intensive
care unit (PICU) need to be tapered after prolonged use
to prevent iatrogenic withdrawal syndrome (IWS).
 We evaluated IWS and sedation before and after
conversion from intravenous midazolam to oral loraze-
pam in patients under 18 years of age.
 The weaning protocol was not always able to prevent
IWS, but converting from intravenous midazolam to oral
lorazepam did not increase the incidence.
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metabolism due to age or other factors influencing drug
exposure, such as critical illness. In addition to this, the
bioavailability of oral lorazepam in children is unknown
and, therefore, no correction is possible for a potential
incomplete bioavailability. In summary, this means that the
current dosage of lorazepam for weaning of midazolam may
not be optimal. At the time of our study, no clinical data on
the conversion from midazolam to lorazepam in PICU
settings were available in the literature.
Due to this limited information, the aim of this study
was to evaluate the occurrence of IWS and the level of
sedation before and after conversion from intravenous
midazolam to oral lorazepam. We also wanted to assess
the safety of our current midazolam to lorazepam conver-
sion protocol.
METHODS
Design and study population
A retrospective, single center, cohort study was performed
to evaluate the move from intravenous midazolam to oral
lorazepam to keep patients comfortable and prevent IWS.
Our study population was admitted to the level five PICU of
the Erasmus MC - Sophia Children’s Hospital, Rotterdam,
The Netherlands, between January 2013 and December
2014. Patients were selected from our Critical Care Suite
electronic patient data management system (Picis Clinical
Solutions SA, Barcelona, Spain), when they had received
oral lorazepam following intravenous midazolam. The
exclusion criteria were the use of midazolam and lorazepam
for epilepsy or delirium, when the latter had been diagnosed
by a trained psychiatrist, or for other reasons such as
incidental sleep medication. The medical ethics committee
of the hospital waived the need for institutional review
board approval and informed consent according to the
Dutch law on Medical Human Research.
IWS and sedation scores
To achieve optimal weaning, it is necessary to monitor
symptoms of IWS from benzodiazepines and opioids and to
monitor the level of sedation. These are assessed using
the Sophia Observation withdrawal Symptoms (SOS)
scale to determine IWS and the COMFORT behaviour
(COMFORT-B) scale to assess the level of sedation (6–8).
The SOS scale consists of 15 items representing signs and
symptoms of opioid and/or benzodiazepine withdrawal,
including changes in heart and respiratory rate and signs of
discomfort. IWS scoring is initiated at start of weaning and
performed at eight-hour intervals, when the occurrence of
IWS is suspected, and to evaluate any interventions that
were made to treat IWS. The COMFORT-B scale consists of
six behavioural items and is applied in combination with
the Nurses Interpretation of Sedation Score (NISS) (6)
from the start of mechanical ventilation. It has been
validated to assess the level of sedation in ventilated and
nonventilated children. Scoring is performed by the attend-
ing nurses at eight-hour intervals and if there are signs of
distress or increasing discomfort. It continues until
discharge from the PICU or until all sedative medication
has been stopped.
Weaning protocol
Weaning of sedative and analgesic medication is initiated as
soon as the patient’s underlying condition and pathology
improve, their electrolytes are within normal range and they
are cardiovascularly stable. The protocol for weaning of
continuous opioids and sedatives implemented at our PICU
starts with decreasing continuous infusion rates of the drugs
and the intervals depend on the preceding length of
treatment. Infusion rates are decreased, one drug at a time,
by 10% of the initial rate. This occurs every 24 hours when
the patient has received the drug for six to nine days and
every 48 hours when they have received the drug for
10 days or more. The intravenous medication is converted
to an effect-equivalent dose of oral medication within the
same therapeutic class when the patient is due to be
discharged to the general ward without cardiorespiratory
monitoring, when intravenous access is no longer required
or available or when prolonged weaning is expected. The
initial daily dose of oral lorazepam is calculated by dividing
the daily dose of midazolam by 12. This conversion is based
on the lorazepam and midazolam ratio for half-life (6:1) and
its relative potency (2:1) in adults (5). This lorazepam dose is
administered orally four times a day, and the intravenous
midazolam is tapered over 24 hours as shown in Figure 1.
Lorazepam is subsequently tapered in steps of 10% of the
initial dose every 24 or 48 hours. If there are withdrawal
symptoms, indicated by an SOS score of four or more, a
rescue dose of 0.1 mg/kg midazolam is administered or the
oral lorazepam dose is increased to the previous strength. If
applicable, opioids and other sedatives, such as morphine,
fentanyl, clonidine and pentobarbital, are also converted to
oral alternatives in a similar manner, for example metha-
done, clonidine per os and phenobarbital, preferably with a
minimum of 48 hours between conversions. They are
tapered according to the same principles.
Figure 1 Tapering of midazolam after substitution with oral lorazepam. The
intravenous midazolam dose is halved after the second administration of
lorazepam, again halved after the third administration of lorazepam and ceased
after the fourth administration of lorazepam (24 hours after switch). The first
dose of lorazepam is calculated upon the last infusion rate of midazolam.
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Medication
Intravenous midazolam was administered using a Perfusor
FM syringe pump (B BraunMedical, Oss, The Netherlands),
in concentrations of 1 or 5 mg/mL dissolved in 5% glucose,
which were prepared by the pharmacy. Oral midazolam for
rescue administrations was available as an extemporaneous
liquid of 1 mg/mL. Oral lorazepam was administered as
either commercial tablets, extemporaneous capsules of
0.1 mg or a 4 mg/mL commercial injection fluid that was
administered orally. Solid dosage forms were usually dis-
persed in water and administered through a feeding tube.
Data collection
Data were extracted from the electronic medical records.
The clinical and demographic parameters that were
retrieved included age, sex, diagnosis, cumulative doses
and duration of midazolam and lorazepam therapy, anal-
gesic and sedative co-medication and the patient’s destina-
tion after their discharge from the PICU.
Outcomes
The SOS scores were retrieved to determine the incidence
of withdrawal from 48 hours before substitution to
48 hours after substitution. A cut-off score of at least four
was defined as withdrawal. The COMFORT-B scores and
NISS were analysed from 48 hours before substitution to
48 hours after substitution to determine the level of seda-
tion. COMFORT-B scores of ≥23 or 11–22 with a NISS of
one were regarded as undersedation, COMFORT-B scores
of 11–22 with a NISS of two were regarded as adequate
sedation and COMFORT-B scores of ≤10 or 11–22 with a
NISS of three were regarded as oversedation. Similarly, the
number of rescue dosages of midazolam and other sedatives
were compared from 48 hours before to 48 hours after
substitution. The frequency and severity of apnoeas and the
need for flumazenil during the 48 hours after start of
lorazepam were used to assess the safety of the conversion.
Apnoeas were registered manually in the patient data
management system by the attending physician or nurse
as part of standard care. The agreement of the actual
midazolam to lorazepam conversion with the conversion
protocol was assessed with respect to the dose calculation
of lorazepam and the tapering of midazolam within
24 hours after conversion.
Analysis
Data were analysed using IBM SPSS statistics version 21.0
(IBM Corporation, New York, NY, USA). Demographic
and clinical data were processed using descriptive statistics.
The number of rescue administrations of midazolam and
other sedatives before and after substitution were compared
using a paired-sample t-test.
RESULTS
During the 24-month study period between January 2013
and December 2014, 111 cases met the inclusion criterion
for oral lorazepam use after intravenous midazolam
therapy. After excluding three patients who started loraze-
pam in 2012, 20 patients who received lorazepam for other
purposes than weaning, and excluding multiple occasions
within one subject (n = 9), 79 cases were included for
further analysis. The patient characteristics are listed in
Table 1.
At the point of the midazolam to lorazepam switch, the
median duration of midazolam infusion, from the day of
admittance to the Sophia Children’s Hospital, was 12 days
(range 1–69), and the median cumulative dose was
46.5 mg/kg (range 0.47–287). We also noted that 23
patients were still on invasive ventilation, and 11 patients
had received midazolam at infusion rates that were higher
than 0.35 mg/kg/h during their admission. Further infor-
mation on the patients’ sedative treatment during PICU
admission is summarised in Table 2.
The SOS scores were available for 32 of 79 (40.5%) of the
patients in the 48 hours before substitution and 39 of 79
(49.4%) of the patients in the 48 hours after substitution.
The median score per patient before the start of lorazepam
ranged between 0 and 9.0, with 15 patients (19.0%) having
one or more SOS score of at least four, indicating IWS.
After the start of lorazepam, the median score per patient
ranged between 0 and 5.0, with 17 patients (21.5%) having
Table 1 Patient characteristics (n = 79)
Parameter n %
Sex
Male 37 46.8
Female 42 53.2
Age, median (months) (IQR) 5.3 (1.7–19.8)
Age
0–27 days 13 16.5
28 days–11 months 40 50.6
12–23 months 8 10.1
2–11 years 16 20.2
12–18 years 2 2.5
Weight, median (kg) (IQR) 5.5 (3.6–10.0)
Reason for PICU admission
Cardiac 30 28.0
Noncardiac surgical 4 5.1
Neurological 1 1.3
Infection/respiratory 19 24.1
Trauma 2 2.5
Congenital 9 11.4
Other 14 17.7
Ventilation 79 100
ECMO therapy 7 8.9
Transfer after PICU
Home 7 8.9
Other hospital 18 22.8
Other department 45 57.0
Mortality 9 11.4
Median length of PICU stay
Days (range) 32 (4–183)
ECMO = Extracorporeal membrane oxygenation; IQR = interquartile range;
PICU = paediatric intensive care unit.
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one or more SOS score of at least four. In eight of these 17
patients, the morphine infusion rates were decreased during
the 96 hours around conversion. Figure 2 shows the range
of the highest SOS score per patient within our study
period. Seven patients experienced IWS both before and
after substitution, and 11 patients experienced both overse-
dation and IWS in the 48 hours after substitution.
COMFORT-B scores were available for 77 of 79 patients
(97.5%). All the available scores are shown in Figure 3, with
a median of three scores per patient per day. From a total of
1122 COMFORT-B scores, 136 incidences of oversedation
and 150 incidences of undersedation were determined, in
combination with the NISS, during the 96-hour study
period. Only 44 of the incidences of undersedation were
accounted for by COMFORT-B scores of at least 23 and the
other 106 by a COMFORT-B score between 11 and 22 and
a NISS of one.
In some patients, the COMFORT-B scores, in combina-
tion with the NISS, were outside the adequate sedation
range and these are presented in Figure 4. This Figure shows
that the incidence of oversedation increased after substitu-
tion with lorazepam. During the two days before substitu-
tion, 13 and 16 patients, respectively, experienced
oversedation compared to 39 and 30 patients in the two
days after substitution. Undersedation decreased from 28
and 21 patients before lorazepam initiation to 16 and 13
patients after the start of lorazepam.
A total of 34 patients (43.0%) received one or more
rescue administrations of midazolam before substitution,
compared to 19 patients (24.1%) after substitution, with a
95% confidence interval (95% CI) of 0.06 to 0.77,
p = 0.096. Furthermore, 29 patients (36.7%) received res-
cue administrations of other sedatives before substitution
compared to 21 patients (26.6%) after substitution (95% CI:
0.18 to 0.94, p = 0.178). In total, 50 patients (63.3%)
received rescue administrations before substitution and 34
patients (43.0%) after substitution with a median of two
administrations in both periods. During the 48-hour post-
substitution period, 56 patients (70.9%) continued their
sedative or analgesic co-medication. Co-medication was
decreased in 44 patients and increased in three patients.
Regarding the safety of the substitution, no apnoeas were
reported, and no flumazenil was prescribed during the
96 hours around the conversion.
Adherence to the conversion protocol was variable. The
median midazolam/lorazepam dose ratio was 11.4 (range
1.31–22.6), and 62.0% of the ratios were between 10 and 14.
In 45.6% of the patients, midazolam was tapered in a time
frame of 24 hours from substitution, in agreement with the
protocol. In 32.9%, intravenous midazolam was discontin-
ued before 24 hours and in 21.5%, simultaneous adminis-
tration of intravenous midazolam and oral lorazepam
continued for more than 24 hours.
Table 2 Sedative treatment characteristics during PICU admission (n = 79)
Parameter Median (range) Unit
Median dose per patient
Midazolam* 130 (30–393) mcg/kg/h
Lorazepam† 0.30 (0.08–2.76) mg/kg/d
Cumulative dose
Midazolam‡ 46.5 (0.47–287) mg/kg
Lorazepam 1.42 (0.08–79.32) mg/kg
Maximum infusion rate before subsitution
Midazolam 300 (12–1000) mcg/kg/h
Duration of infusion until substitution
Midazolam 12 (1–69) days
Duration of midazolam therapy
until substitution§ n %
<5 days 3 3.8
5–10 days 16 20.3
>10 days 60 75.9
Duration of lorazepam taper Days (range)
Lorazepam¶ 22 (3–97) (n = 45)
Fixed-interval and continuous sedative
and analgesic co-medication n %
Alimemazine po 10 13
Clonidine
iv 41 52
po 23 29
Esketamine iv 26 33
Fentanyl iv 9 11
Methadone po 16 20
Morphine iv 73 92
Pentobarbital iv 3 4
Propofol iv 19 24
po = orally; iv = intravenous; PICU = paediatric intensive care unit.
*Throughout PICU admission.
†Starting dose at substitution.
‡Until substitution.
§Midazolam therapy was calculated from the first administration to the last
administration in the Sophia Children’s hospital. The short administration of
one day is due to the transfer from another hospital.
¶n = 45. Total lorazepam duration, including use at home. Only the patients
with complete postclinical duration were used to calculate the median.
Figure 2 Distribution of the highest SOS score per patient during the first
48 hours before substitution (grey bars) and 48 hours after substation (open
bars) of iv midazolam with oral lorazepam. Maximum score is 15, with scores ≥4
indicating withdrawal.
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DISCUSSION
Our midazolam to lorazepam switch protocol to prevent
IWS appeared to be effective in the majority of patients, as
no increase in the occurrence of IWS was detected.
Nevertheless, at least 20% of patients still experienced
withdrawal symptoms, while almost 40% showed signs of
oversedation in the early stages after conversion.
Based upon the available SOS scores, the incidence of
IWS was similar before and after conversion to lorazepam.
A limitation is that only about half of the patients were
scored for withdrawal, making the results hard to extrap-
olate. When we assume that the exhibition of IWS symp-
toms is a trigger to start collecting SOS scores, the absence
of SOS scores may be seen as a sign that the patients were
doing well, but this needs to be verified in a prospective
setting. Furthermore, the SOS scale cannot discriminate
between opioid and benzodiazepine withdrawal. This
means that the reported IWS cannot unequivocally be
attributed to benzodiazepine withdrawal, especially in the
eight patients where morphine was tapered simultaneously.
Nevertheless, we did not observe an increase in IWS after
the conversion to lorazepam.
The incidence of IWS in critically ill children has been
reported to range from 13 to 87% (8–19). This large
variation was the result of small sample sizes, a large
variety in often unvalidated assessment methods and
nonstandardised or absent sedation protocols and weaning
regimens. Identified risk factors for IWS are cumulative
doses of midazolam greater than 40 mg/kg (8,11), infusion
of opioids and benzodiazepines for more than five days
(8,11,13) and midazolam infusion rates above 0.35–
0.42 mg/kg/h (18,19). Taking into consideration, the clin-
ical patient characteristics, such as the high cumulative
doses of midazolam and long PICU stays, it becomes
Figure 3 Histograms of available COMFORT-B scores during the four different study periods. The window between the dotted lines show scores that are regarded as
adequate sedation, while lower scores (≤10) are regarded as oversedation and higher scores (≥23) as undersedation.
Figure 4 Oversedation: COMFORT-B scores ≤10 or 11–22 with NISS = 3.
Adequate sedation: COMFORT-B scores of 11–22 with NISS = 2. Undersedation:
COMFORT-B scores ≥23 or 11–22 with NISS = 1. For study periods 1–4,
respectively 7, 9, 11 and 6 children were both under- and oversedated.
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apparent that the patients in our cohort were at high risk for
developing IWS. In our retrospective cohort, based upon
the available SOS scores, IWS was diagnosed in one-fifth of
the patients, both before and after substitution.
The majority of the collected COMFORT-B scores were
within the target range for adequate sedation, with a
tendency towards more oversedation postsubstitution. This
could suggest supratherapeutic dosages of sedatives, espe-
cially during the first 24 hours in which midazolam and
lorazepam were simultaneously administered. To put these
findings into perspective, COMFORT-B scores of nine and
10 could be the result of a comfortably asleep child with
normal muscle and facial tone and is not necessarily
indicative of an unsafe situation. Considering it may take
a number of days to reach steady-state plasma levels of
lorazepam due to its long half-life, it seems rational to start
with lorazepam while phasing out midazolam to ensure
adequate exposure. The absence of apnoeas and flumazenil
administration during the study period provides evidence
that the combined blood levels of benzodiazepines were not
within the toxic range. It is notable that several patients
experienced both oversedation and withdrawal after sub-
stitution, which illustrates the complexity of managing IWS.
The comparison of rescue administrations of midazolam
and other sedatives yielded no statistically significant
results.
The lorazepam dose calculation was based on the relative
half-life and potency of lorazepam versus midazolam, as
determined in adult patients, and irrespective of individual
patient characteristics. Lorazepam is primarily metabolised
through conjugation with glucuronic acid by multiple
hepatic UDP-glucuronosyltransferase enzymes, to inactive
metabolites. The maturation rates of involved enzyme
systems differ between the subtypes, but may well extend
beyond the age of two years, based upon gene expression
data and in vivo experiments (20,21). Paediatric pharma-
cokinetic data after the oral administration of lorazepam
are unavailable. At the moment, there are insufficient data
available to establish an age-dependent conversion factor.
Midazolam pharmacokinetics in paediatric patients are well
studied and are highly dependent on CYP3A4 activity. High
blood levels of midazolam might be caused by delayed
clearance due to immature metabolism at a neonatal age
(22), ongoing inflammation and critical illness (23), co-
medication, accumulation of its active metabolites after
prolonged use (19) or renal insufficiency (24). None
of these factors are currently considered in the dose
calculation.
This retrospective analysis of a weaning strategy reflects
clinical practice in patients in a complex, intensive care
setting. We acknowledge that our study had several limita-
tions. Although COMFORT-B scores were taken regularly,
we found that SOS scores were underreported. In addition,
the lorazepam dose calculation in some patients was based
upon the midazolam dosage rate at the moment of conver-
sion instead of the cumulative dose of the last 24 hours,
resulting in different dosing strategies. Since 2017, a
lorazepam extemporaneous oral liquid of 1 mg/mL has
been available (25). As a result, oral administration of
injection fluid is no longer applied and capsules are no
longer used. The dose conversion is now checked by the
attending pharmacist. One further limitation was that the
concomitant use of other central nervous depressants was
common during PICU stays in our study, and this hindered
the attribution of the observations to the conversion from
midazolam to lorazepam.
In the past two decades, considerable progress has been
made in recognising the need for weaning-off sedation
strategies in PICUs. Risk factors for the development of
IWS have been identified, and scoring systems have been
validated and implemented to monitor the patients. This
study was the first to specifically address the use of oral
lorazepam in the weaning-off sedation strategy in PICU
patients.
CONCLUSION
The weaning protocol for sedatives using lorazepam did not
increase the incidence of IWS and appeared to be safe. A
better understanding of the factors that explain variations in
both pharmacokinetics and pharmacodynamics may help
us to further tailor weaning strategies to the individual
patient.
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